ArticleOncotarget2017
Incidence and survival differences in esophageal cancer among ethnic groups in the United States.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Efficacy and safety of tislelizumab in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.Journal of the Egyptian National Cancer Institute · 2025Pooled it
- Inflammatory Biomarkers from Blood Counts as Prognostic Tools in Metastatic Esophageal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Survival and Treatment Patterns in Stage II to III Esophageal Cancer.JAMA network open · 2024Article
- Improvement of esophageal cancer survival in Northeast Iran: A two-decade journey in a high-risk, low- resource region.PloS one · 2024Article
- Global comparative transcriptomes uncover novel and population-specific gene expression in esophageal squamous cell carcinoma.Infectious agents and cancer · 2023Article
- Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma.Cancer medicine · 2023Article
- Effect of vascular endothelial growth factor rs35569394 in esophageal cancer and response to chemotherapy.Biomolecules & biomedicine · 2023Article
- Race and Ethnicity, Stage-Specific Mortality, and Cancer Treatment in Esophageal and Gastric Cancers: Surveillance, Epidemiology, and End Results (2000-2018).Gastroenterology · 2023Article
- Disparities in thoracic surgical oncology.Journal of surgical oncology · 2023Review
- Factors associated with access and approach to esophagectomy for cancer: a National Cancer Database study.Surgical endoscopy · 2022Article
- Endoscopic diagnosis and screening of Barrett's esophagus: Inconsistency of diagnostic criteria between Japan and Western countries.DEN open · 2022Review
- Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin.Journal of oncology · 2022Article
- Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer.Scientific reports · 2021Observational
- Inferred Ancestral Origin of Cancer Cell Lines Associates with Differential Drug Response.International journal of molecular sciences · 2021Article
- Exome sequencing identifies novel somatic variants in African American esophageal squamous cell carcinoma.Scientific reports · 2021Article
- The Life-Long Role of Nutrition on the Gut Microbiome and Gastrointestinal Disease.Gastroenterology clinics of North America · 2021Review
- Sex-Associated Gene Expression Alterations Correlate With Esophageal Cancer Survival.Clinical and translational gastroenterology · 2020Article
- Efficacy and feasibility of OverStitch suturing of leaks in the upper gastrointestinal tract.Surgical endoscopy · 2020Article
- Racial and ethnic disparities in mortality from gastric and esophageal adenocarcinoma.Cancer medicine · 2020Article
- Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.Advances in therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study was performed to identify the differences in incidence, clinicopathological features, and survival in esophageal cancer among ethnic groups in the United States and to determine the reasons for the differences.
resultA total of 49,766 patients were included. Black and Asian groups had a higher proportion of squamous cell carcinoma (ESCC) (85.5% and 75.4%, respectively) and mid-esophagus tumor (43.2% and 37.7% respectively) than the non-Hispanic white and Hispanic white groups. The incidences of ESCC in all ethnic groups declined since 1973, especially in black males. At the same time, incidences of esophageal adenocarcinoma (EAC) dramatically increased in white males since 1973. And incidences of ESCC and EAC were the lowest and stable in Asian female. Multivariable models showed that patients who were male, or black, or had larger tumors, or positive lymph nodes had an increased risk of death from esophageal cancer, while patients with ESCC or diagnosed after 2005 or treated with surgery had a lower likelihood of death. For ESCC, the black patients had the lowest DSS, while for EAC there were no significant differences in DSS among the ethnic/racial groups. MATERIALS AND
methodFrom the Surveillance, Epidemiology, and End Results Program database, patients diagnosed with esophageal cancer from 1998-2013 were identified. Differences in incidences, clinicopathological features, treatments, and disease-specific survival (DSS) in four broad racial/ethnic groups were compared.
conclusionHistological type distribution between racial groups could be an important consideration in the incidence and the survival trend but other factors could also have an effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.